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Abstract 
 
Patients who are consuming antithrombotic drugs, both anticoagulants and antiplatelet, are very at risk of bleeding 
complications after dental extraction or minor oral surgical treatment. But interrupting the consumption of antithrombotic 
drugs which are inappropriate will trigger thrombosis side effects that can endanger the patient. Therefore the operator 
must have good insight regarding the types of antithrombotic drugs that are often used so that the operator is able to make 
the right decision when we should stop or continue the surgical treatment. This review aims to optimize minor oral 
surgery and dental extraction prosedures management of patients on antithrombotic drug administration. Antithrombotic 
drugs are generally classified into two groups. Those are namely antiplatelet and anticoagulant. Antiplatelet can inhibit 
platelet aggregation, so that it will prevent thrombus formation in blood vessels whereas the anticoagulant group can 
inhibit thrombus formation by blocking the hemostasis cascade. The selection of surgical treatment on patients with 
antithrombotic drugs administration must be depend on both antiplatelet and anticoagulant type which is used by the 
patient. The conclusion are in accordance with the current literature, It’s very important to make decision properly about  
the tromboembolic event risk if those antithrombotic drugs are discontinued, and It would stimulate bleeding event if we 
want to continue the drug administration. 
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Abstrak 
 
Pasien yang sedang mengonsumsi obat antitrombotik, baik antikoagulan maupun antiplatelet, sangat beresiko mengalami 
komplikasi perdarahan pasca ekstraksi gigi atau perawatan bedah mulut minor. Namun tindakan penghentian konsumsi 
obat antitrombotik yang tidak tepat akan memicu efek samping trombosis yang dapat membahayakan pasien. Oleh 
karena itu operator harus memiliki wawasan yang baik terkait jenis obat antitrombotik yang sering digunakan sehingga 
operator mampu membuat keputusan yang tepat kapankah harus menghentikan atau melanjutkan perawatan bedah. 
Ulasan ini bertujuan untuk mengoptimalkan manajemen bedah mulut kecil dan prosedur perawatan ekstraksi gigi pada 
pasien dengan pemberian obat antitrombotik. Obat antitrombotik secara umum terbagi menjadi dua kelompok. Keduanya 
adalah antiplatelet dan antikoagulan. Antiplatelet dapat menghambat agregasi tombosit, sehingga mampu menghambat 
pembentukan trombus didalam pembuluh darah sedangkan kelompok antikoagulan dapat menghambat pembentukan 
trombus dengan memblokir kaskade hemostasis. Pemilihan perawatan bedah pada pasien dengan pemberian obat 
antitrombotik harus bergantung pada jenis antiplatelet dan antikoagulan yang digunakan oleh pasien. Kesimpulan sesuai 
dengan literatur saat ini, Sangat penting untuk membuat keputusan dengan tepat terkait resiko kejadian tromboemboli 
jika obat antitrombotik dihentikan, dan hal ini dapat menstimulasi terjadinya perdarahan jika kita ingin melanjutkan 
pemberian obat. 
 
Kata Kunci : obat antitrombotik, bedah mulut minor, tromboemboli, perdarahan. 
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INTRODUCTION 
 
Bleeding complication during oral surgical treat-
ment can be serious problem. The bleeding may dis-
turb surgeon’s visibility and makes the other compli-
cation. Bleeding can occur while the blood vessel is 
cut. Bleeding complication which is caused by trau-
ma can be handled by applying pressure on the 
wound site. The surgeon usually use gauge to give 
adequate pressure.
1
 
Bleeding may also occur excessively on patients 
with antithrombotic administration. Antithrombotic 
administration was the key role treatment in syn-
drome of acute coronary. Antithrombotic drugs can 
reduce platelet aggregation and inhibit clotting for-
mation process.
2  
Antithrombotic drugs are generally 
classified into two groups. Those are namely anti-
platelet and anticoagulant. Antiplatelet can inhibit 
platelet aggregation so that it will prevent thrombus 
formation in blood vessels whereas the anticoagulant 
group can inhibit thrombus formation by blocking 
the hemostasis cascade inside the body.
3 
Patients suffering venous thromboembolism, myo-
cardial infarction require antithrombotic drugs to pre-
vent acute coronary syndrome which is caused by 
partial or complete closure of the arterial lumen that 
can be detected by angiography or biopsy.
2,4,5
 The 
closure of the vessel lumen is caused by thrombus 
formation in blood vessels. Antithrombotic drugs are 
needed in these cases because they can inhibit pla-
telet accumulation so that thrombus formation can be 
prevented.
2,3
 
The prevalence of patients receiving  anticoagulant 
therapy has increased significantly  in  recent  years. 
Over  800.000  patients from spain, dominated by at-
rial fibrillation cases, have accepted anticoagulants 
therapy. Antiplatelet  drugs are also given as general 
treatment for atherosclerotic disease. This medical 
history information exactly may help the surgeon to 
identify about the antithrombotic drug types which 
are consumed by the patient.
6
 
The management before the surgery in patients,
 
who have been receiving antithrombotic therapy
 
and 
will undergo surgery and also invasive measures, 
needs very appropriate consideration especially with 
temporary cessation of antithrombotic drugs admi-
nistration. Antithrombotic drugs administration ma-
nagement requires very appropriate strategy. We 
may perform surgery but we should avoid bleeding 
complications and also the thrombosis event. The 
operator should consider appropriately all of the risks 
of each anticoagulant and antiplatelet drugs tem-
porary cessation. Proper consideration must be ap-
plied, so the adverse effect of the drugs may be de-
creased at the lowest level.
7,8 
Hemostasis is physiological response of the vessel 
when it is injured by stimulating clot formation to 
stop bleeding event. Meanwhile, thrombosis is patho-
logical response of the body which overactivated in 
clot formation proscess in the absence of bleeding 
condition. It happens because the body maintains 
blood fluidity as physiological process. Hemostasis is 
caused by the interaction of the virchows triad. The 
interaction between blood flow, blood composition 
and endothelial cells affect the thrombotic event.
9
 
There are three major steps in hemostasis. Those 
are vasoconstriction, blood clot formation, and coa-
gulation. The first is immediate blood vessels vaso-
constriction. After blood vessels are injured, para-
crine hormone is released by endothelial cells which 
stimulates blood vessels constriction. The second is 
plug formation which is formed by platelet accu-
mulation. This plug will block the blood flow at the 
injury site so the hemorrhage may be decreased. It 
may happen because the platelets, which attached to 
the exposed collagen surfaces, will stimulate platelet 
activation to release several cytokines such as sero-
tonin, thromboxane A2, and endotelin. These cyto-
kines may stimulate other platelets to form platelet 
plug. The cytokine also stimulate vasoconstriction of 
the blood vessels. The exposed collagen surfaces also 
initiate the series of coagulation cascade. The clotting 
cascade is generally classified into two pathways. 
Those are  intrinsic pathway and the extrinsic path-
way. In the intrinsic pathway, exposed collagen will 
initiate the clotting by binding factor 12. Meanwhile, 
the extrinsic pathway is mainly activated by tissue 
factor. Tissue factor can be released by tissue injury. 
Fibrin fiber formation is stimulated by procoagulant 
factors such as fibrinogen, factor V and von wil-
lebrand factor which are released by platelets. In the 
common pathway, thrombin will convert the fib-
rinogen to fibers.
10
 These fibers will become mesh 
like, and it can bind the platelets together. These fib-
rin fibers also can stick the platelet to the inside wall 
of the blood vessels, where the injury site is located.
9
 
Thrombosis is pathological response of the body 
that overactivated in the clot formation process in the 
absence of bleeding condition. Thrombosis occurs in 
the syndrome of acute coronary which becomes the 
primary cause of any cardiovascular disease. Throm-
bosis can  be stimulated by lipid which is covered by 
atheromatous plaque. Atheromatous plaque can be 
cracked and release lipid constituent. This may also 
stimulate platelets attachment to the injury site which 
could be activated and it stimulates further platelet 
accumulation. When the platelets are around the 
plaque, it will change their fabrics of glycoprotein 
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IIb/IIIa receptors to bind fibrinogen. This formation 
will make a complex platelet linkage. These platelet 
aggregations could occlude partially or the lumen of 
blood vessels. Thus, this condition may obstruct 
blood flow.
11 
Antithrombotic drugs have several mechanisms 
which can inhibit platelet aggregation, fibrin fibers 
formation and ruin the clots which have been 
formed. In general, antihrombotic drugs are divided 
into two groups. Antithrombotic drugs are generally 
classified into two groups. Those are namely anti-
platelet and anticoagulant each of which has function 
of fibrin formation and thrombus aggregation.
3 
 Antiplatelet inhibits platelet aggregation which 
will prevent thrombus formation in blood vessels. 
Antiplatelet drugs include: aspirin and indobufen  in-
hibit TXA2 synthesis, clopidogrel, prasugrel and ti-
cagrelor that inhibit ADP receptor activation, 
dypiridamole and cilostazol that decrease Ca
++ 
by 
elevating cAMP, abciximab, tirofiban, and eptifi-
batide that block GP Iib/IIIa receptors.
12,13
 
The anticoagulant group inhibits thrombus forma-
tion by inhibiting the hemostasis cascade in the body. 
This anticoagulant group is divided into four classes, 
namely vitamin K antagonists (include warfarin), he-
parin (include unfractionated and low molecular he-
parin), Novel or direct oral anticoagulants com-
prising Xa factor inhibitors and thrombin inhi-
bitors.
14,15 
For many decades, warfarin and heparin which are 
combined with aspirin as anti plateletes are usually 
used for acute coronary syndromes. Recently, prac-
titioners have developed oral anticoagulant drugs 
such as novel direct oral anticoagulant drugs. These 
drugs may specifically inhibit thrombin or factor Xa 
which are coagulation enzymes. One of the advan-
tage using these drugs are minimal bleeding event. 
Moreover, this novel oral anticoagulant drugs are 
better preventing agent for thromboembolism.  
Heparin is generally divided into two groups. 
Those are unfractionated heparin and low molecular 
weight heparin. Heparin is usually used for venous 
thromboembolism treatment and acute coronary syn-
dromes. There is a difference between unfractionated 
heparin and low molecular weight heparin in their 
application. Unfractionated heparin is usually used 
intravenously whereas low molecule heparin is 
usually used subcutaneously. Both anticoagulants 
have a fast onset anticoagulation.
16 
Heparin can sti-
mulate hemorrhagic effect, because it can bind anti-
thrombin III and deactivates factors IIa dan Xa.
17 
Vitamin K antagonists has been used as antico-
agulation treatment for stroke prevention for more 
than fifty years. As long anticoagulant therapy, war-
farin has been proven to be effective therapy on 
stroke prevention. Vitamin K antagonist drugs could 
reduce the stroke rate until 60%. Vitamin K anta-
gonist drugs could inhibit posttranslational car-
boxylation of coagulation factors. Vitamin K anta-
gonist could inhibit Xa factor, therefore it can pre-
vent prothrombin to be thrombin.
18
  
Novel or new direct oral anticoagulant (DOAC) 
drugs have been found as advance anticoagulant 
drugs which have spesific target in coagulation cas-
cade. DOAC has been proven as good as vitamin K 
anticoagulant (warfarin) drugs outcome, but it has 
minimal bleeding effect than vitamin K antico-
agulant. Many reports which have reported that 
DOAC has been proven very effective as stroke pre-
vention therapy. It can prevent the atherothrombotic 
event which occurs after acute coronary syndrome.
19 
All of novel or new direct oral anticoagulant 
(DOAC) types have a selective action to coagulation 
factor. Apixaban, edoxaban and rivaroxaban can in-
hibit factor Xa, whereas dabigatran inhibit especially 
thrombin.
19 
One of the difference between DOAC 
and vitamin K antagonist is the half life of the drug. 
Warfarin has longer half life than DOAC. Warfarin 
has half life which is 40 hours, whereas DOAC has 
shorter half life which is eight to twelve hours. More-
ver, DOAC has fast onset after oral administration. 
DOAC has fast onset which is in two to four hours.
19 
Aspirin is antiplatelet drug which is the most pres-
cribed. Aspirin is usually used in ischemic heart di-
seases, because it can inhibit cyclooxygenase activity 
in arachidonic acid metabolism. Aspirin  inhibits cy-
clooxygenase 2 enzym to stimulate the thromboxane 
A2 production which is strong chemoattractant for 
platelet recruitment. Aspirin can be used as a single 
drug or used in combination in dual antiplatelet the-
rapy with clopidogrel. Aspirin is usually used in 
combination with anticoagulant drugs such as he-
parin and warfarin.
20
 
Clopidogrel is antiplatelet drug which is member 
of thienopyridines. Clopidogrel is usually used in 
myocardial infarction and also unstable angina for 
preventing vascular occlusive. Moreover clopidogrel 
was developed by chemical modifying of previously 
adenosine diphosphate antagonist drug which is tic-
lopidine. Clopidogrel also has minimal bleeding ef-
fect than ticlopidine.
20
 
Clopidogrel has selective action to the adenosine 
diphosphate, so that it has capacity to inhibit platelet 
accumulation. Moreover clopidogrel can inhibit the 
activation of the glycoprotein GPIIb/IIIa receptor 
which is located on the platelet surface and become 
the major receptor for fibrinogen.
20
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DISCUSSION 
 
Bleeding risks management in dental surgical treat-
ment of patient on antithrombotic drugs therapy 
should be considered properly to prevent throm-
boembolic or bleeding complication. Incorrect termi-
nation of antithrombotic drug can stimulate throm-
boembolic event, whereas bleeding complication 
may occur if the operator continue the antithrombotic 
drug consumption.
2,14
 
The first, the operator must know about the me-
dical history of the patient and how long the patient 
will receive antithrombotic drug therapy. Patients 
who have used prosthetic heart valves and also ar-
terial or venous stent require cardiologist written per-
mission to alter the antithrombotic medication. Pa-
tients who have used prosthetic heart valves and also 
arterial or venous stent has higher risk of bleeding 
complication. For the patients who receive short life 
antithrombotic drugs therapy, dental extraction or 
minor oral surgical treatment can be delayed until the 
end of antithrombotic medication, whereas the pa-
tients who receive long life antithrombotic drugs the-
rapy, the drugs therapy can be stopped temporarily.
14
 
The second, the operator must know the type of 
antithrombotic drugs which is used by the patient, 
because the decision is also determined by this as-
pect. Such as aspirin, ibuprofen and diclofenac have 
been proven that can exacerbate the bleeding com-
plication after its administration. Moreover, patients 
receiving aspirin medication as single drug don’t 
need to stop consuming the drug temporarily, be-
cause it can be handled by using local hemostatic.
13
 
Local hemostatic agent is usually used in dental 
practice to stop bleeding occurrence. It can be used 
after tooth extraction and also odontectomy surgery 
which is applied in the socket before we put suture. 
Local hemostatic is generally classified in to two ca-
tegory, active agent (such as thrombin, tannic acid, 
albumin, and etc), and passive agent (such as col-
lagen, cellulose, and gelatin). The active agent of he-
mostatic can influence directly to coagulation cas-
cade so it can stimulate the clot formation, whereas 
the passive agent provide a framework for platelet 
aggregation.
1 
The patients, who consume anticoagulant medi-
cation, will have anticoagulant effect until the fifth 
day. Therefore, if the patient will undergo dental ex-
traction or minor oral surgical treatment, it should be 
delayed until the fifth day. Vitamin K antagonist 
such as warfarin has longer half-life which is 40 
hours, whereas novel direct oral anticoagulant has 
shorter half-life which is eight to twelve hours. Ac-
cording to those informations, if the patients have 
been receiving novel direct oral anticoagulant medi-
cation, the surgical treatment can be performed ear-
lier after the termination of the drug consumption, 
whereas the patients who have been receiving medi-
cation have to delay the surgical treatment until the 
fourth day.
14
 
Patients who don’t use prosthetic valve or arterial 
and venous stent are not allowed to alter the antico-
agulant medication. Moreover, the patient appoint-
ment should be performed in the morning because 
bleeding complication could be handled adequately 
during the appointment.
14
  
Almost the same as management of patients recei-
ving anticoagulant drugs, the operator must know the 
antiplatelet drug types that have been used by the pa-
tient. Because there is no single report that temporary 
aspirin cessation can result in thromboembolic 
events, the dentist may discontinue aspirin medi-
cation without the cardiologist permission.
13
 More-
over, some studies had proven dental surgical treat-
ment on patients, who have used aspirin medication 
in single or dual platelet, can be safely performed 
when the operator uses appropriate local hemostatic 
agents.
13
 
Another research report had also reported that ap-
propriate local hemostatic could prevent bleeding 
event in patients using antiplatelet drugs. Lillis et al 
(2011). monitored 111 patients receiving antipletelet 
medication. Those patients consist of 42 patients 
using aspirin, 36 patients using clopidogrel, and 42 
patients using dual antiplatelet drugs (aspirin com-
bined with clopidogrel). All of those patients had per-
formed dental extraction and the bleeding compli-
cations were successfully handed by applying local 
haemostatic agent.
21
 
Although using appropriate local hemostatic agent 
is recommended to prevent bleeding complication, 
the dentist should consider the number and the regio-
nal of the teeth which will be extracted. The first, 
teeth extraction, which will be performed in the 
single session, shouldn’t more than 3 teeth to prevent 
bleeding complication. The second, if we will extract 
molar teeth which is located in the same regional of 
the dental arch, the dentist is only allowed to extract 
one molar tooth. It is not allowed to extract two-mo-
lar adjacent teeth in the same session.
13 
It can be concluded that a dentist requires sufficient 
knowledge related to minor oral surgery and dental 
extraction procedures management of patients using 
antithrombotic drugs. The dentist should understand 
the types, effects  of antithrombotic drugs which is 
used by patient, so the dental management can be 
done properly.
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